• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic lands reimbursement for MiniMed 670G pump in Germany

September 9, 2019 By Nancy Crotti

MedtronicMedtronic logo updated (NYSE:MDT) said today it has secured reimbursement for its MiniMed 670G insulin pump system from regulators in Germany.

The German Federal Association of the Statutory Health Insurances (GKV-SV) granted reimbursement for the smart insulin pump for patients with type 1 diabetes, according to the company.

In May, Medtronic released real-world data from more than 8 million patient days that showed patients using the MiniMed 670G spent more time in a healthy blood glucose range.

The MiniMed 670G is designed to automatically track and adjust blood sugar levels, using a continuous glucose monitor, guiding patients toward a minimum level of 120 mg/dL. Medtronic first won FDA approval for the MiniMed 670G in September 2016.

“We have already seen the difference the MiniMed 670G system has had for tens of thousands of people living with type 1 diabetes across the world who are now experiencing better clinical and quality of life outcomes,” said Medtronic diabetes group chief medical officer Dr. Robert Vigersky in a news release. “Reimbursement in Germany will increase the access of this life-changing technology to more individuals who would benefit from it.”

The reimbursement agreement took effect on August 29, 2019, according to Medtronic. The company said it expects the approval to be announced in the Federal Gazette  (Bundesanzeiger) in the coming weeks.

Filed Under: Auto-injectors, Diabetes, Featured, Uncategorized, Wall Street Beat

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS